Veradermics 2025 Financial Results, IPO & VDPHL01 Updates

NEW HAVEN, Conn. - Veradermics, Incorporated (NYSE: MANE), a late clinical-stage biopharmaceutical company, announced its financial results for the fourth quarter and full year ended December 31, 2025, alongside significant corporate and clinical advancements. The company emphasized its transformation into a public entity following a successful upsized Initial Public Offering (IPO) in February 2026, which raised approximately $294.8 million in gross proceeds.

Reid Waldman, M.D., CEO of Veradermics, highlighted 2025 as a landmark year, driven by progress in Phase 3 development of VDPHL01, their lead investigational drug for pattern hair loss (PHL). The company anticipates two Phase 3 readouts for male patients in 2026 and aims for a New Drug Application (NDA) submission, while also advancing the first-ever Phase 3 trial of an oral treatment for female PHL. With a robust balance sheet, Veradermics expects its current cash, cash equivalents, and marketable securities to fund operations into 2029, covering multiple anticipated Phase 3 readouts and the potential commercial launch of VDPHL01, if approved.

... Read on — Members only